SLAS2016 Short Courses

Affinity-based, Biophysical Methods for Screening and Mechanistic Studies

Who Should Attend:

How You Will Benefit From This Course:

Get a broad overview about what is available and state of the art in the field

Course Topics:

Overview of the most relevant biochemical biophysics/ label-free technologies for screening and lead finding

Course Pre-Reading Requirements:

Instructor Bios:

Christine Genick / Novartis Institutes for BioMedical Research Basel, Center for Proteomic Chemistry

Dr. Christine Genick has been working since 2000 in the field of label free technologies, not only on the development of technologies for screening, but also in the utilization of these approaches for lead finding in drug discovery. In 2009, Chris joined the Screening Sciences Group at Novartis, as a laboratory head in charge of biophysical hit validation for HTS, FBS, and focused screen follow-up. In 2015, she joined the Structural Biophysics Group and in conjunction with her current responsibilities, she is the Core Biophysics Technology Representative, which entails searching for new applications, technologies, and approaches to detect small molecule binding interactions with target proteins. Chris also heads the SPR Core Facility for NIBR and manages various types of exploratory projects involving biophysics.

Stefan Geschwindner / AstraZeneca R&D Mölndal, Discovery Sciences, Structure & Biophysics

Dr. Stefan Geschwindner has already during his Ph.D. worked with label-free technologies, predominantly with NMR to elucidate protein structures. Stefan joined the Astra Structural Chemistry Laboratory as a Senior Research Scientist in 1998 with focus on protein production and characterization applying a variety of biophysical methods. Before moving into his current role as Principal Scientist in Biophysics at AstraZeneca in 2006, he had different roles as Team leader in Protein Engineering as well as Delivery leader for Neuroscience. During this last decade, Stefan has frequently applied biophysical methods to facilitate the mechanistic understanding of protein-ligand interactions and to enable fragment-based lead generation approaches. He has the shared responsibility and an excellent track record for developing and implementing new biophysical approaches to aid early lead finding activities.